B-Cell Lymphoblastic Leukemia Clinical Trials

3 recruiting

Frequently Asked Questions

Common questions about B-Cell Lymphoblastic Leukemia clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 18 of 8 trials

Recruiting

A Multi-site Study to Evaluate the Persistence of Protective Immunity to Routine Childhood Vaccinations in Participants With B-ALL/Ly Who Have Received Blinatumomab

B-cell Acute Lymphoblastic LeukemiaB-Cell Lymphoblastic LeukemiaB-cell Acute Lymphoblastic Leukemia (B-ALL)+5 more
Arkansas Children's Hospital Research Institute300 enrolled2 locationsNCT07422337
Recruiting
Phase 2

Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Acute Lymphoblastic LeukemiaB-Cell Lymphoblastic Leukemia
H. Lee Moffitt Cancer Center and Research Institute60 enrolled1 locationNCT06144606
Recruiting
Phase 1Phase 2

Nanobody-Based CD19/CD22 Tandem Dual CAR-T Therapy for R/R B-ALL

Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
Peking University People's Hospital30 enrolled1 locationNCT06880913
Recruiting
Phase 1Phase 2

CD19 & CD22 Bispecific CAR T Cells in the Treatment of Relapsed/Refractory B Cell Hematologic Tumors

B-Cell Lymphoblastic Leukemia/Lymphoma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology80 enrolled1 locationNCT06735495
Recruiting
Phase 2Phase 3

Efficacy Study of Blinatumomab Clean Up Early Residual Disease for Newly Diagnosed Pediatric B Lymphoblastic Leukemia

B-Cell Lymphoblastic Leukemia
Shanghai Jiao Tong University School of Medicine90 enrolled4 locationsNCT06607419
Recruiting
Phase 2

Blinatumomab Plus Venetoclax Sequenced With Inotuzumab Ozogamicin in Treating B-ALL

Precursor B-Cell Lymphoblastic Leukemia
First Affiliated Hospital of Zhejiang University20 enrolled1 locationNCT06554626
Recruiting
Phase 1Phase 2

CD19 & CD20 Bispecific CAR T Cells for Relapsed / Refractory B Cell Hematological Tumors

B-Cell Lymphoblastic Leukemia/Lymphoma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology80 enrolled1 locationNCT06503094
Recruiting
Phase 4

Blinatumomab for Relapsed Acute B Lymphoblastic Leukemia After Transplantation

Acute B-cell Lymphoblastic Leukemia
Suping ZHANG60 enrolled1 locationNCT06339775